Analysts Set TScan Therapeutics, Inc. (NASDAQ:TCRX) Price Target at $6.00

by · The Markets Daily

Shares of TScan Therapeutics, Inc. (NASDAQ:TCRX – Get Free Report) have earned a consensus rating of “Hold” from the six analysts that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $6.00.

A number of research firms recently issued reports on TCRX. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd. Wall Street Zen lowered TScan Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a research report on Tuesday, April 21st. Finally, Wedbush restated an “outperform” rating and set a $5.00 price objective on shares of TScan Therapeutics in a research report on Tuesday, June 23rd.

Get Our Latest Research Report on TScan Therapeutics

TScan Therapeutics Trading Up 0.3%

NASDAQ:TCRX opened at $0.98 on Wednesday. The business’s 50-day moving average is $1.06 and its two-hundred day moving average is $1.05. The company has a debt-to-equity ratio of 0.34, a current ratio of 6.65 and a quick ratio of 6.65. TScan Therapeutics has a 12 month low of $0.83 and a 12 month high of $2.57. The firm has a market capitalization of $64.05 million, a PE ratio of -1.02 and a beta of 1.03.

TScan Therapeutics (NASDAQ:TCRX – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.22). The company had revenue of $0.98 million for the quarter, compared to the consensus estimate of $2.50 million. TScan Therapeutics had a negative return on equity of 91.94% and a negative net margin of 1,360.61%. Research analysts predict that TScan Therapeutics will post -1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On TScan Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Aberdeen Group plc lifted its position in TScan Therapeutics by 31.8% in the fourth quarter. Aberdeen Group plc now owns 1,785,241 shares of the company’s stock worth $1,785,000 after purchasing an additional 430,421 shares during the period. Renaissance Technologies LLC lifted its position in TScan Therapeutics by 37.5% in the fourth quarter. Renaissance Technologies LLC now owns 1,141,069 shares of the company’s stock worth $1,141,000 after purchasing an additional 311,150 shares during the period. Jane Street Group LLC lifted its position in TScan Therapeutics by 377.5% in the fourth quarter. Jane Street Group LLC now owns 388,284 shares of the company’s stock worth $388,000 after purchasing an additional 306,968 shares during the period. Marshall Wace LLP lifted its position in TScan Therapeutics by 627.5% in the fourth quarter. Marshall Wace LLP now owns 339,240 shares of the company’s stock worth $339,000 after purchasing an additional 292,610 shares during the period. Finally, XTX Topco Ltd lifted its position in TScan Therapeutics by 1,142.5% in the fourth quarter. XTX Topco Ltd now owns 219,001 shares of the company’s stock worth $219,000 after purchasing an additional 201,375 shares during the period. 82.83% of the stock is currently owned by institutional investors and hedge funds.

About TScan Therapeutics

(Get Free Report)

TScan Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of T-cell receptor (TCR) therapies for the treatment of cancer. Leveraging its proprietary T-Scan platform, the company seeks to identify high-affinity TCRs that recognize intracellular tumor antigens presented on the surface of cancer cells. TScan’s approach aims to broaden the reach of immunotherapy beyond current targets by unlocking a wider array of cancer-associated proteins.

The company’s pipeline includes multiple preclinical and early-stage clinical programs in both hematologic malignancies and solid tumors.

Featured Stories